Nektar autoimmune drug shows promise in alopecia study, despite missing statistical success, supporting late-stage testing.
Author: PharmaSignal News Desk
FDA fast pass J&J for multiple myeloma regimen, impacting treatment timelines.
Xoma acquires Generation Bio, a gene therapy developer, in a strategic move to enhance its biotech portfolio.
Argenx halts two Vyvgart trials for thyroid eye disease after interim results show ineffectiveness, impacting potential market expansion.
Sanofi Tolebrutinib setback includes a Phase 3 failure in primary progressive MS and a delayed US approval decision.
Arcus Gilead trial cancellation marks a setback in cancer research as the TIGIT/PD-1 study is halted for futility, impacting future strategies.
Praxis epilepsy drug approval filing is planned for early 2025 after collaborative discussions with the FDA. Rezolute shares fell, Centessa named a new CEO.
AC Immune Parkinson’s drug shows positive data, prompting regulatory feedback request. Shares rise by double-digits.
Apple Tree Ventures files for bankruptcy amid a funding dispute with billionaire backer, affecting its startups and restructuring plans.
Lilly retatrutide obesity drug demonstrates up to 29% weight loss in Phase 3 study, setting a new benchmark for competitors.